指南与共识类风湿关节炎脊柱关节炎系统性红斑狼疮

风湿病学试验中共享决策干预的OMERACT核心结局集领域定义与描述的共识

Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials.
指南 / 共识 · Semin Arthritis Rheum · 2024-01-15

风湿病学结局测量(OMERACT)工作组按OMERACT手册方法,通过六次虚拟会议及邮件交流起草领域定义与描述,并对52名成员(含15名患者研究伙伴、33名临床医生和37名研究者)进行国际调查以达成共识。患者研究伙伴与临床医生/研究者对所有定义和描述的同意率为87%至100%,最终工作组就共享决策干预试验核心领域集的领域定义与描述达成共识。

要点

  • 工作组就风湿病学共享决策干预试验核心领域集的领域定义与描述达成共识。
  • 52名成员完成调查,患者研究伙伴与临床医生/研究者对所有定义和描述的同意率为87%至100%。
  • 该共识为理解各领域及确定各领域测量工具以纳入核心结局测量集奠定基础。

核心结论

  • 工作组就风湿病学共享决策干预试验核心领域集的领域定义与描述达成共识。
  • 该步骤对理解每个领域至关重要,并为确定测量每个领域的工具以纳入核心结局测量集提供了基础。

研究设计与样本

  • 本研究为OMERACT工作组共识制定项目,遵循OMERACT手册方法。
  • 工作组由90名成员组成,包括17名患者研究伙伴和73名临床医生与研究者,通过六次虚拟会议及邮件交流起草定义与描述。
  • 工作组随后对其成员开展国际调查以就定义与描述达成共识,最终通过虚拟会议和邮件交流审核调查结果并定稿领域名称、定义与描述。

主要发现

  • 52名成员完成调查,代表四大洲和13个国家,包括15名患者研究伙伴、33名临床医生和37名研究者。
  • 患者研究伙伴与临床医生/研究者对所有定义和描述的同意率为87%至100%。
  • 受访者建议对名称、定义和描述进行措辞修改以更好地反映各领域,讨论进一步简化和澄清以回应关于各领域的常见问题/疑虑。

关键数值与推荐

  • 患者研究伙伴与临床医生/研究者对所有定义和描述的同意率为87%至100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To gain consensus on the definitions and descriptions of the domains of the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials evaluating shared decision making (SDM) interventions. METHODS: Following the OMERACT Handbook methods, our Working Group (WG), comprised of 90 members, including 17 patient research partners (PRPs) and 73 clinicians and researchers, had six virtual meetings in addition to email exchanges to develop draft definitions and descriptions. The WG then conducted an international survey of its members to gain consensus on the definitions and descriptions. Finally, the WG members had virtual meetings and e-mail exchanges to review survey results and finalize names, definitions and descriptions of the domains. RESULTS: WG members contributed to developing the definitions. Fifty-two members representing four continents and 13 countries completed the survey, including 15 PRPs, 33 clinicians and 37 researchers. PRPs and clinicians/researchers agreed with all definitions and descriptions with agreements ranging from 87% to 100%. Respondents suggested wording changes to the names, definitions and descriptions to better reflect the domains. Discussions led to further simplification and clarification to address common questions/concerns about the domains. CONCLUSION: Our WG reached consensus on the definitions and descriptions of the domains of the core domain set for rheumatology trials of SDM interventions. This step is crucial to understand each domain and provides the foundation to identify instruments to measure each domain for inclusion in the Core Outcome Measurement Set. CLINICAL SIGNIFICANCE: The current study provides consensus-based definitions and descriptions for the domains of the OMERACT core domain set for shared decision making interventions from patients/caregivers, clinicians and researchers. This is a crucial step to understand each domain and provides the foundation to identify instruments to measure each domain for inclusion in the Core Outcome Measurement Set for trials of SDM interventions.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Décary S, de Wit M, Naye F, et al. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials. Semin Arthritis Rheum. 2024. PMID: 38306813. doi:10.1016/j.semarthrit.2024.152381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。